Mutation profiling in differential diagnosis between TdT-positive high-grade/large B-cell lymphoma and B-lymphoblastic leukaemia/lymphoma.

IF 5.2 2区 医学 Q1 ONCOLOGY
Maria-Myrsini Tzioni, Francesco Cucco, Lívia Rásó-Barnett, Zi Chen, Andrew Wotherspoon, Katrin S Kurz, Ewelina Madej, Jasmine Makker, Anna E Strazda, Fang Guo, Caoimhe Egan, Elizabeth Soilleux, Liz Hook, Laszlo Krenacs, Julia T Geyer, Camille Laurent, Luc Xerri, Lenaïg Mescam, Lukas Plank, Lise Mette Rahbek Gjerdrum, Nicolas Lopez-Hisijos, Timothy Greiner, Joseph Khoury, Wolfram Klapper, Ilske Oschlies, Andreas Rosenwald, German Ott, Ming-Qing Du
{"title":"Mutation profiling in differential diagnosis between TdT-positive high-grade/large B-cell lymphoma and B-lymphoblastic leukaemia/lymphoma.","authors":"Maria-Myrsini Tzioni, Francesco Cucco, Lívia Rásó-Barnett, Zi Chen, Andrew Wotherspoon, Katrin S Kurz, Ewelina Madej, Jasmine Makker, Anna E Strazda, Fang Guo, Caoimhe Egan, Elizabeth Soilleux, Liz Hook, Laszlo Krenacs, Julia T Geyer, Camille Laurent, Luc Xerri, Lenaïg Mescam, Lukas Plank, Lise Mette Rahbek Gjerdrum, Nicolas Lopez-Hisijos, Timothy Greiner, Joseph Khoury, Wolfram Klapper, Ilske Oschlies, Andreas Rosenwald, German Ott, Ming-Qing Du","doi":"10.1002/path.6476","DOIUrl":null,"url":null,"abstract":"<p><p>Terminal deoxynucleotidyl transferase (TdT) is occasionally expressed in large B-cell lymphoma (LBCL), and this causes difficulty in differential diagnosis from B-lymphoblastic leukaemia/lymphoma (B-ALL/LBL). We reviewed 31 cases of TdT-positive LBCL and B-ALL/LBL, and their final diagnosis included 19 diffuse large/high-grade BCLs with MYC and BCL2 rearrangements (five DLBCL-MYC/BCL2, 14 HGBCL-MYC/BCL2), three DLBCL not otherwise specified (NOS), three HGBCL-NOS, four B-ALL/LBL, and two unclassifiable cases. TdT was variably expressed in all these cases, without any clear demarcation among different groups. Loss or partial loss of CD20 expression was seen in 13/17 DLBCL/HGBCL-MYC/BCL2, 2/3 HGBCL-NOS, and 2/2 unclassified, albeit not in DLBCL-NOS. Expression of BCL6 and/or MUM1 was seen in 3/4 B-ALL/LBLs and 2/2 unclassified. Next-generation sequencing revealed characteristic mutations associated with follicular lymphoma and its high-grade transformation in each DLBCL/HGBCL-MYC/BCL2, and also frequent variants in genes targeted by somatic hypermutation (SHM) in almost all DLBCL/HGBCL-MYC/BCL2, DLBCL-NOS, and HGBCL-NOS but one case. In contrast, such mutations were absent in B-ALL/LBL. There were no pathognomonic mutations in the two unclassifiable cases, although one showed a moderate level of somatic mutations in its rearranged IGHV. Furthermore, in three cases of TdT-positive HGBCL-MYC/BCL2, studies of previous or concurrent follicular lymphoma demonstrated their divergent evolution from an IGH::BCL2-positive cell population following acquisition of MYC translocation. In conclusion, mutation profiling analysis including the SHM target genes is highly valuable in the differential diagnosis between TdT-positive LBCL and B-ALL/LBL. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.</p>","PeriodicalId":232,"journal":{"name":"The Journal of Pathology","volume":" ","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/path.6476","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Terminal deoxynucleotidyl transferase (TdT) is occasionally expressed in large B-cell lymphoma (LBCL), and this causes difficulty in differential diagnosis from B-lymphoblastic leukaemia/lymphoma (B-ALL/LBL). We reviewed 31 cases of TdT-positive LBCL and B-ALL/LBL, and their final diagnosis included 19 diffuse large/high-grade BCLs with MYC and BCL2 rearrangements (five DLBCL-MYC/BCL2, 14 HGBCL-MYC/BCL2), three DLBCL not otherwise specified (NOS), three HGBCL-NOS, four B-ALL/LBL, and two unclassifiable cases. TdT was variably expressed in all these cases, without any clear demarcation among different groups. Loss or partial loss of CD20 expression was seen in 13/17 DLBCL/HGBCL-MYC/BCL2, 2/3 HGBCL-NOS, and 2/2 unclassified, albeit not in DLBCL-NOS. Expression of BCL6 and/or MUM1 was seen in 3/4 B-ALL/LBLs and 2/2 unclassified. Next-generation sequencing revealed characteristic mutations associated with follicular lymphoma and its high-grade transformation in each DLBCL/HGBCL-MYC/BCL2, and also frequent variants in genes targeted by somatic hypermutation (SHM) in almost all DLBCL/HGBCL-MYC/BCL2, DLBCL-NOS, and HGBCL-NOS but one case. In contrast, such mutations were absent in B-ALL/LBL. There were no pathognomonic mutations in the two unclassifiable cases, although one showed a moderate level of somatic mutations in its rearranged IGHV. Furthermore, in three cases of TdT-positive HGBCL-MYC/BCL2, studies of previous or concurrent follicular lymphoma demonstrated their divergent evolution from an IGH::BCL2-positive cell population following acquisition of MYC translocation. In conclusion, mutation profiling analysis including the SHM target genes is highly valuable in the differential diagnosis between TdT-positive LBCL and B-ALL/LBL. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

tdt阳性高级别/大b细胞淋巴瘤和b淋巴母细胞白血病/淋巴瘤的鉴别诊断中的突变分析
末端脱氧核苷酸转移酶(TdT)偶尔在大b细胞淋巴瘤(LBCL)中表达,这给b淋巴细胞白血病/淋巴瘤(B-ALL/LBL)的鉴别诊断带来了困难。我们回顾了31例tdt阳性的LBCL和B-ALL/LBL,最终诊断包括19例弥漫性大/高级别bcl伴MYC和BCL2重排(5例DLBCL-MYC/BCL2, 14例HGBCL-MYC/BCL2), 3例无特异性DLBCL (NOS), 3例HGBCL-NOS, 4例B-ALL/LBL, 2例无法分类。TdT在所有病例中的表达都是可变的,不同组之间没有明确的界限。CD20表达缺失或部分缺失在13/17 DLBCL/HGBCL-MYC/BCL2、2/3 HGBCL-NOS和2/2未分类患者中可见,但在DLBCL- nos中未见。BCL6和/或MUM1在3/4的B-ALL/LBLs和2/2的未分类中表达。新一代测序显示,在每个DLBCL/HGBCL-MYC/BCL2中,滤泡性淋巴瘤的特征性突变及其高级别转化,并且在几乎所有DLBCL/HGBCL-MYC/BCL2、DLBCL- nos和HGBCL-NOS中,除了一例外,体细胞超突变(SHM)靶向基因也频繁变异。相比之下,这种突变在B-ALL/LBL中不存在。在这两个无法分类的病例中,没有病理突变,尽管其中一个在其重排的IGHV中显示出中等水平的体细胞突变。此外,在三例tdt阳性HGBCL-MYC/BCL2病例中,既往或并发滤泡性淋巴瘤的研究表明,在MYC易位获得后,它们从IGH::BCL2阳性细胞群进化而来。总之,包括SHM靶基因在内的突变谱分析在tdt阳性LBCL和B-ALL/LBL的鉴别诊断中具有很高的价值。©2025作者。《病理学杂志》由John Wiley & Sons Ltd代表大不列颠和爱尔兰病理学会出版。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
The Journal of Pathology
The Journal of Pathology 医学-病理学
CiteScore
14.10
自引率
1.40%
发文量
144
审稿时长
3-8 weeks
期刊介绍: The Journal of Pathology aims to serve as a translational bridge between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The main interests of the Journal lie in publishing studies that further our understanding the pathophysiological and pathogenetic mechanisms of human disease. The Journal of Pathology welcomes investigative studies on human tissues, in vitro and in vivo experimental studies, and investigations based on animal models with a clear relevance to human disease, including transgenic systems. As well as original research papers, the Journal seeks to provide rapid publication in a variety of other formats, including editorials, review articles, commentaries and perspectives and other features, both contributed and solicited.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信